Bookmark and Share

Compound Summary for: CID 208908

lapatinib

Also known as: 231277-92-2; GW572016; Tykerb; GW 572016; Tycerb; 1xkk; Lapatinib (INN); Lapatinib [INN]; UNII-0VUA21238F
Molecular Formula: C29H26ClFN4O4S   Molecular Weight: 581.057543   InChIKey: BCFGMOOMADDAQU-UHFFFAOYSA-N
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Biomedical Effects and Toxicity
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _